Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma

The goal of this clinical trial is to learn about radiofrequency ablation in patients with unresectable bile duct cancer who receive systemic chemotherapy and bile duct stenting. The main questions it aims to answer are: * Does radiofrequency ablation of tumorous bile duct occlusion reduce risk of complications in these patients (eg stent dysfunction, delay of chemotherapy, infections etc)? * Is radiofrequency ablation safe in these patients? All participants will receive standard treatment with systemic chemotherapy and bile duct stenting. Researchers will compare two groups (one group will

Trial Details

NCT ID
NCT06175845
Phase
NA
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Intraductal biliary radiofrequency ablation
Locations (sample)
  • Berlin, Germany|52.52437,13.41053
  • Bonn, Germany|50.73438,7.09549
  • Chemnitz, Germany|50.8357,12.92922
  • Essen, Germany|51.45657,7.01228
  • Hamburg, Germany|53.55073,9.99302

Key Eligibility Criteria

  • Unresectable perihilar and/or ductal CCA with bile duct stenting and palliative systemic therapy as indicated by the local Multidisciplinary Team (…
  • Written informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Age ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →